AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 9551674 — intervention group
Group type: EXPERIMENTAL
Intervention: Long-term sustained virologic response
Number of subjects: 71
Study 8822160 — intervention group
Group type: EXPERIMENTAL
Intervention: Blocking the visuospatial sketchpad (by manipulation of a keypad)
Number of subjects: 0
Study 8822160 — intervention group
Group type: EXPERIMENTAL
Intervention: Blocking the central executive (by random letter generation)
Number of subjects: 0
Study 8822160 — intervention group
Group type: EXPERIMENTAL
Intervention: Spatial secondary task (random generation of keypresses)
Number of subjects: 0
Study 8822160 — intervention group
Group type: EXPERIMENTAL
Intervention: Verbal secondary task (vocal generation of random numbers)
Number of subjects: 0
Study 8822160 — intervention group
Group type: COMPARATOR
Intervention: Control condition
Number of subjects: 0
Study 2248740 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of antibiotics (amoxicillin) and oral steroids (prednisone)
Number of subjects: 136
Study 2248740 — intervention group
Group type: COMPARATOR
Intervention: Amoxicillin
Number of subjects: 136
Study 2248740 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 136
Study 7358200 — intervention group
Group type: EXPERIMENTAL
Intervention: Loxapine (10-150 mg/day)
Number of subjects: 0
Study 7358200 — intervention group
Group type: COMPARATOR
Intervention: Thioridazine (150-750 mg/day)
Number of subjects: 0
Study 7358200 — intervention group
Group type: EXPERIMENTAL
Intervention: Both Loxapine and Thioridazine
Number of subjects: 0
Study 31787001 — intervention group
Group type: EXPERIMENTAL
Intervention: Repair of pronator quadratus muscle
Number of subjects: 72
Study 31787001 — intervention group
Group type: COMPARATOR
Intervention: Non-repair of pronator quadratus muscle
Number of subjects: 72
Study 27664232 — intervention group
Group type: EXPERIMENTAL
Intervention: Cardiogoniometry
Number of subjects: 114
Study 27664232 — intervention group
Group type: COMPARATOR
Intervention: Exercise‐ECG test
Number of subjects: 114
Study 26216164 — intervention group
Group type: EXPERIMENTAL
Intervention: Group Cognitive‐Behavioral Therapy
Number of subjects: 43
Study 26216164 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluoxetine
Number of subjects: 43
Study 23893527 — intervention group
Group type: EXPERIMENTAL
Intervention: Lisdexamfetamine dimesylate (LDX)
Number of subjects: 317
Study 23893527 — intervention group
Group type: EXPERIMENTAL
Intervention: Osmotic-release oral system methylphenidate (OROS-MPH)
Number of subjects: 317
Study 23893527 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 317
Study 20940383 — intervention group
Group type: EXPERIMENTAL
Intervention: Buprenorphine implants (4 implants, 80 mg each)
Number of subjects: 163
Study 20940383 — intervention group
Group type: COMPARATOR
Intervention: Placebo implants (4 implants)
Number of subjects: 163
Study 20940383 — intervention group
Group type: EXPERIMENTAL
Intervention: Buprenorphine implants
Number of subjects: 163
Study 18426577 — intervention group
Group type: EXPERIMENTAL
Intervention: Relora (250 mg capsules, 3 times daily for 6 weeks)
Number of subjects: 40
Study 18426577 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study 18426577 — intervention group
Group type: EXPERIMENTAL
Intervention: Relora
Number of subjects: 40
Study 16629006 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention to increase use of hearing protection devices
Number of subjects: 0
Study 16629006 — intervention group
Group type: EXPERIMENTAL
Intervention: Transtheoretical model framework
Number of subjects: 0
Study 14582585 — intervention group
Group type: EXPERIMENTAL
Intervention: Triclosan-containing dental gel (0.3%) applied for 5 min twice daily for 14 days
Number of subjects: 14
Study 14582585 — intervention group
Group type: COMPARATOR
Intervention: Placebo gel
Number of subjects: 14
Study 10757567 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol
Number of subjects: 30
Study 10757567 — intervention group
Group type: COMPARATOR
Intervention: Oxycodone-thiopental
Number of subjects: 30
Study 8699068 — intervention group
Group type: EXPERIMENTAL
Intervention: SPf66 synthetic vaccine
Number of subjects: 0
Study 8699068 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 2021589 — intervention group
Group type: EXPERIMENTAL
Intervention: Phenylephrine drops (10%) with modified dropper tip (smaller volume)
Number of subjects: 0
Study 2021589 — intervention group
Group type: COMPARATOR
Intervention: Phenylephrine drops (10%) with normal dropper tip (normal volume)
Number of subjects: 0
Study 7129028 — intervention group
Group type: EXPERIMENTAL
Intervention: Labyrinthine stimulation (ear irrigation with ice water)
Number of subjects: 4
Study 7129028 — intervention group
Group type: COMPARATOR
Intervention: Control stimulation (ear irrigation at 37 degrees C)
Number of subjects: 4
Study 7129028 — intervention group
Group type: COMPARATOR
Intervention: No stimulation
Number of subjects: 4
Study 7129028 — intervention group
Group type: EXPERIMENTAL
Intervention: Labyrinthine stimulation
Number of subjects: 4
Study 30590833 — intervention group
Group type: EXPERIMENTAL
Intervention: Sarilumab 150 mg s.c. every 2 weeks
Number of subjects: 0
Study 30590833 — intervention group
Group type: EXPERIMENTAL
Intervention: Sarilumab 200 mg s.c. every 2 weeks
Number of subjects: 0
Study 30590833 — intervention group
Group type: COMPARATOR
Intervention: Tocilizumab 4 mg/kg i.v. every 4 weeks
Number of subjects: 0
Study 30590833 — intervention group
Group type: COMPARATOR
Intervention: Tocilizumab 8 mg/kg i.v. (if clinically indicated)
Number of subjects: 0
Study 30590833 — intervention group
Group type: EXPERIMENTAL
Intervention: Sarilumab and Tocilizumab (both studies)
Number of subjects: 0
Study 29087903 — intervention group
Group type: EXPERIMENTAL
Intervention: MARP plus home neuromuscular electrical stimulation therapy (n = 23)
Number of subjects: 44
Study 29087903 — intervention group
Group type: COMPARATOR
Intervention: MARP alone (n = 21)
Number of subjects: 44
Study 29087903 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined rehabilitation cohort
Number of subjects: 44
Study 25773566 — intervention group
Group type: EXPERIMENTAL
Intervention: Clinical chronic obstructive pulmonary disease questionnaire (CCQ)
Number of subjects: 0
Study 24610309 — intervention group
Group type: EXPERIMENTAL
Intervention: Revascularization (PCI/CABG)
Number of subjects: 39131
Study 23618054 — intervention group
Group type: EXPERIMENTAL
Intervention: Educational policing strategy (letters, incident reports, covert audits, feedback meetings)
Number of subjects: 21
Study 23618054 — intervention group
Group type: EXPERIMENTAL
Intervention: Educational policing strategy (intensive police response)
Number of subjects: 21
Study 19941765 — intervention group
Group type: EXPERIMENTAL
Intervention: Indirect pulp treatment (IPT) with calcium hydroxide (CH) or gutta‐percha (GP)
Number of subjects: 18
Study 19941765 — intervention group
Group type: COMPARATOR
Intervention: Positive control group (sound molars)
Number of subjects: 18
Study 19941765 — intervention group
Group type: COMPARATOR
Intervention: Negative control group (carious teeth)
Number of subjects: 18
Study 17599568 — intervention group
Group type: EXPERIMENTAL
Intervention: Unaltered prosthesis head size
Number of subjects: 9
Study 17599568 — intervention group
Group type: EXPERIMENTAL
Intervention: Reduced prosthesis head size
Number of subjects: 9
Study 17599568 — intervention group
Group type: EXPERIMENTAL
Intervention: Augmented prosthesis head size
Number of subjects: 9
Study 17599568 — intervention group
Group type: COMPARATOR
Intervention: Comparison of all three head sizes (unaltered, reduced, augmented)
Number of subjects: 9
Study 15366589 — intervention group
Group type: EXPERIMENTAL
Intervention: Huannao Yicong capsule (HYC) 3 capsules, 3 times daily for 2 months
Number of subjects: 62
Study 15366589 — intervention group
Group type: COMPARATOR
Intervention: Hydergin 3 tablets, 3 times daily for 2 months
Number of subjects: 62
Study 15366589 — intervention group
Group type: EXPERIMENTAL
Intervention: Huannao Yicong capsule (HYC)
Number of subjects: 62
Study 11329558 — intervention group
Group type: EXPERIMENTAL
Intervention: Training from a standardized patient
Number of subjects: 98
Study 11329558 — intervention group
Group type: COMPARATOR
Intervention: Lecture/demonstration class
Number of subjects: 98
Study 10024707 — intervention group
Group type: EXPERIMENTAL
Intervention: Active treatment (ear electroacupuncture with two needles at an active site and self-retained ear seeds for two weeks)
Number of subjects: 78
Study 10024707 — intervention group
Group type: COMPARATOR
Intervention: Placebo treatment (ear electroacupuncture with two needles at a placebo site and self-retained ear seeds for two weeks)
Number of subjects: 78
Study 7981930 — intervention group
Group type: EXPERIMENTAL
Intervention: Colestipol (10 g)
Number of subjects: 6
Study 7981930 — intervention group
Group type: EXPERIMENTAL
Intervention: Cholestyramine (8 g)
Number of subjects: 6
Study 7981930 — intervention group
Group type: COMPARATOR
Intervention: Water only (control)
Number of subjects: 6
Study 3054010 — intervention group
Group type: EXPERIMENTAL
Intervention: Nimodipine
Number of subjects: 213
Study 3054010 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 213
Study 31632269 — intervention group
Group type: EXPERIMENTAL
Intervention: Pidotimod 800 mg b/d for 21 consecutive days per month for 6 months (V1 group)
Number of subjects: 40
Study 31632269 — intervention group
Group type: COMPARATOR
Intervention: No drug (V0 group)
Number of subjects: 40
Study 28860174 — intervention group
Group type: EXPERIMENTAL
Intervention: Lower-body negative pressure (LBNP; -10 mmHg)
Number of subjects: 14
Study 28860174 — intervention group
Group type: EXPERIMENTAL
Intervention: Lower-body positive pressure (LBPP; +10 mmHg)
Number of subjects: 14
Study 28860174 — intervention group
Group type: EXPERIMENTAL
Intervention: High altitude (HA)
Number of subjects: 14
Study 28860174 — intervention group
Group type: COMPARATOR
Intervention: Sea level (SL)
Number of subjects: 14
Study 26212437 — intervention group
Group type: EXPERIMENTAL
Intervention: Entecavir (ETV) treatment
Number of subjects: 69
Study 26212437 — intervention group
Group type: COMPARATOR
Intervention: Virological response (patients with ETV treatment)
Number of subjects: 69
Study 23199101 — intervention group
Group type: EXPERIMENTAL
Intervention: Total arch distalization using orthodontic mini‐implants (OMIs) combined with interproximal stripping (IPS)
Number of subjects: 66
Study 23199101 — intervention group
Group type: COMPARATOR
Intervention: Second premolar extraction
Number of subjects: 66
Study 21889262 — intervention group
Group type: EXPERIMENTAL
Intervention: Nitrous oxide anesthesia
Number of subjects: 640
Study 18835404 — intervention group
Group type: EXPERIMENTAL
Intervention: Two-year multi-component program including classroom activities, development of school Travel Access Guides, parent newsletters, and improving environments with local councils
Number of subjects: 1996
Study 18835404 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified in detail)
Number of subjects: 1996
Study 16482236 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-volume PEG plus sennosides (120 mg oral sennosides syrup followed by 2 L PEG)
Number of subjects: 0
Study 16482236 — intervention group
Group type: COMPARATOR
Intervention: Standard volume PEG (4 L PEG)
Number of subjects: 0
Study 12908830 — intervention group
Group type: EXPERIMENTAL
Intervention: Risperidone (atypical antipsychotic medication)
Number of subjects: 2
Study 12908830 — intervention group
Group type: COMPARATOR
Intervention: Placebo (control)
Number of subjects: 2
Study 12908830 — intervention group
Group type: EXPERIMENTAL
Intervention: Risperidone
Number of subjects: 2
Study 10983914 — intervention group
Group type: EXPERIMENTAL
Intervention: Alendronate (Fosamax)
Number of subjects: 6459
Study 10983914 — intervention group
Group type: EXPERIMENTAL
Intervention: Fair-to-poor self-rated health
Number of subjects: 6459
Study 10983914 — intervention group
Group type: EXPERIMENTAL
Intervention: Four or more depressive symptoms
Number of subjects: 6459
Study 10983914 — intervention group
Group type: EXPERIMENTAL
Intervention: Good self-rated health
Number of subjects: 6459
Study 9498151 — intervention group
Group type: EXPERIMENTAL
Intervention: Nadroparin calcium (Fraxoparine Sanofi France)
Number of subjects: 100
Study 9498151 — intervention group
Group type: COMPARATOR
Intervention: No prophylaxis (Control)
Number of subjects: 100
Study 8149110 — intervention group
Group type: EXPERIMENTAL
Intervention: d-fenfluramine (45 mg/day)
Number of subjects: 43
Study 8149110 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 43
Study 3775603 — intervention group
Group type: EXPERIMENTAL
Intervention: No serum (group 1)
Number of subjects: 53
Study 3775603 — intervention group
Group type: COMPARATOR
Intervention: 10% patient's serum (group 2)
Number of subjects: 53
Study 29439085 — intervention group
Group type: EXPERIMENTAL
Intervention: Behavioural Activation (BA) intervention
Number of subjects: 60
Study 29439085 — intervention group
Group type: COMPARATOR
Intervention: Treatment as usual
Number of subjects: 60
Study 26471280 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention group with printed symptom summaries available before each weekly office visit
Number of subjects: 112
Study 26471280 — intervention group
Group type: COMPARATOR
Intervention: Control group without printed symptom summaries
Number of subjects: 112
Study 23413812 — intervention group
Group type: EXPERIMENTAL
Intervention: Titanium-zirconium alloy narrow diameter implants
Number of subjects: 42
Study 23413812 — intervention group
Group type: COMPARATOR
Intervention: Commercially pure titanium narrow diameter implants
Number of subjects: 42
Study 21942405 — intervention group
Group type: EXPERIMENTAL
Intervention: Resource-building group intervention workshops
Number of subjects: 718
Study 21942405 — intervention group
Group type: COMPARATOR
Intervention: Printed information about career and health-related issues (comparison group)
Number of subjects: 718
Study 20234292 — intervention group
Group type: EXPERIMENTAL
Intervention: Nurse case management (average of 60 min of case management time per month)
Number of subjects: 1551
Study 17606955 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose atorvastatin (80 mg/d)
Number of subjects: 3809
Study 17606955 — intervention group
Group type: COMPARATOR
Intervention: Low-dose atorvastatin (10 mg/d)
Number of subjects: 3809
Study 15617697 — intervention group
Group type: EXPERIMENTAL
Intervention: Ritodrine tocolysis
Number of subjects: 60
Study 15617697 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study 15617697 — intervention group
Group type: EXPERIMENTAL
Intervention: External cephalic version
Number of subjects: 60
Study 11907389 — intervention group
Group type: EXPERIMENTAL
Intervention: Ondansetron (8 mg intravenous)
Number of subjects: 0
Study 11907389 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 11907389 — intervention group
Group type: COMPARATOR
Intervention: Both groups
Number of subjects: 0
Study 10459409 — intervention group
Group type: EXPERIMENTAL
Intervention: AMPT (alpha-methyl-para-tyrosine)
Number of subjects: 6
Study 10459409 — intervention group
Group type: COMPARATOR
Intervention: Placebo (diphenhydramine hydrochloride)
Number of subjects: 6
Study 7887644 — intervention group
Group type: EXPERIMENTAL
Intervention: Arm A: 250 mg/m2 of l‐LV and 600 mg/m2 of 5‐FU weekly
Number of subjects: 73
Study 7887644 — intervention group
Group type: EXPERIMENTAL
Intervention: Arm B: 100 mg/m2 of l‐LV and 370 mg/m2 of 5‐FU for 5 consecutive days
Number of subjects: 73
Study 7887644 — intervention group
Group type: EXPERIMENTAL
Intervention: Arm C: 10 mg/m2 of l‐LV and 370 mg/m2 of 5‐FU for 5 consecutive days
Number of subjects: 73
Study 2403824 — intervention group
Group type: EXPERIMENTAL
Intervention: Native prothrombin antigen (therapeutic range, 12 to 24 micrograms/mL)
Number of subjects: 156
Study 2403824 — intervention group
Group type: COMPARATOR
Intervention: Prothrombin time index (therapeutic range, 1.5 to 2.0)
Number of subjects: 156
Study 240140 — intervention group
Group type: EXPERIMENTAL
Intervention: Alclofenac 500 mg
Number of subjects: 0
Study 240140 — intervention group
Group type: COMPARATOR
Intervention: Indomethacin 25 mg
Number of subjects: 0
Study 31665476 — intervention group
Group type: EXPERIMENTAL
Intervention: High water (HW) intake targeting urine osmolality (UOsm) ≤270 mOsm/kg
Number of subjects: 42
Study 31665476 — intervention group
Group type: EXPERIMENTAL
Intervention: High water (HW) intake
Number of subjects: 42
Study 31665476 — intervention group
Group type: COMPARATOR
Intervention: Ad libitum (AW) intake
Number of subjects: 42
Study 30611157 — intervention group
Group type: EXPERIMENTAL
Intervention: Graduates of pediatric neurosurgery fellowship programs
Number of subjects: 391
Study 29202730 — intervention group
Group type: EXPERIMENTAL
Intervention: Biomarker-guided antibiotic treatment of stroke associated pneumonia
Number of subjects: 229
Study 29202730 — intervention group
Group type: COMPARATOR
Intervention: Patients able to consent
Number of subjects: 229
Study 25911711 — intervention group
Group type: EXPERIMENTAL
Intervention: Sonographic diagnosis for contralateral malignancy
Number of subjects: 143
Study 25911711 — intervention group
Group type: EXPERIMENTAL
Intervention: Sonographic classes IV and V (possibly malignant and malignant)
Number of subjects: 143
Study 23707824 — intervention group
Group type: EXPERIMENTAL
Intervention: Internet counseling (daily e-mails with recommended activities through Pfizer's GetQuit program)
Number of subjects: 217
Study 23707824 — intervention group
Group type: COMPARATOR
Intervention: In-person counseling (four 1.5 hour classes based on the American Cancer Society's Freshstart program)
Number of subjects: 217
Study 22189150 — intervention group
Group type: EXPERIMENTAL
Intervention: Once-daily darunavir/ritonavir (DRV/r) 800/100 mg
Number of subjects: 343
Study 22189150 — intervention group
Group type: COMPARATOR
Intervention: Lopinavir/ritonavir 800/200 mg
Number of subjects: 343
Study 18423977 — intervention group
Group type: EXPERIMENTAL
Intervention: Suspicious DRE
Number of subjects: 5040
Study 18423977 — intervention group
Group type: COMPARATOR
Intervention: Normal DRE
Number of subjects: 5040
Study 17203523 — intervention group
Group type: EXPERIMENTAL
Intervention: Comprehensive treatment (Shehuang Paste + Chinese herbal colon dialysis)
Number of subjects: 75
Study 17203523 — intervention group
Group type: EXPERIMENTAL
Intervention: Simple treatment (Shehuang Paste only)
Number of subjects: 75
Study 17203523 — intervention group
Group type: COMPARATOR
Intervention: Control (basic treatment only)
Number of subjects: 75
Study 17203523 — intervention group
Group type: EXPERIMENTAL
Intervention: Comprehensive treatment
Number of subjects: 75
Study 17203523 — intervention group
Group type: EXPERIMENTAL
Intervention: Simple treatment
Number of subjects: 75
Study 17203523 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 75
Study 14598412 — intervention group
Group type: EXPERIMENTAL
Intervention: Minilaparoscopic cholecystectomy (MLC)
Number of subjects: 135
Study 14598412 — intervention group
Group type: COMPARATOR
Intervention: Traditional laparoscopic cholecystectomy (LC)
Number of subjects: 135
Study 11998122 — intervention group
Group type: EXPERIMENTAL
Intervention: Telephone follow-ups
Number of subjects: 0
Study 8810951 — intervention group
Group type: EXPERIMENTAL
Intervention: Bronchoalveolar lavage (BAL)
Number of subjects: 66
Study 8810951 — intervention group
Group type: COMPARATOR
Intervention: Catheter lavage (CL)
Number of subjects: 66
Study 1454836 — intervention group
Group type: EXPERIMENTAL
Intervention: Tacrine at a dose of 80 mg/day
Number of subjects: 0
Study 1454836 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 6360815 — intervention group
Group type: EXPERIMENTAL
Intervention: Propranolol (non‐selective beta 1 and beta 2 blocker)
Number of subjects: 24
Study 6360815 — intervention group
Group type: EXPERIMENTAL
Intervention: Prazosin (alpha blocker)
Number of subjects: 24
Study 6360815 — intervention group
Group type: EXPERIMENTAL
Intervention: Atenolol (selective beta 1 blocker)
Number of subjects: 24
Study 31583918 — intervention group
Group type: EXPERIMENTAL
Intervention: Norwegian Anterior Knee Pain Scale (AKPS)
Number of subjects: 112
Study 31153977 — intervention group
Group type: EXPERIMENTAL
Intervention: Financial incentive with several contact approaches
Number of subjects: 129
Study 31153977 — intervention group
Group type: COMPARATOR
Intervention: Control group (using the same contact approaches)
Number of subjects: 129
Study 28731883 — intervention group
Group type: EXPERIMENTAL
Intervention: Cancer PEPSONE Program (CPP)
Number of subjects: 35
Study 28731883 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 35
Study 27636923 — intervention group
Group type: EXPERIMENTAL
Intervention: Pulmonary rehabilitation (PR) cycle in addition to standard therapy for COPD
Number of subjects: 70
Study 27636923 — intervention group
Group type: COMPARATOR
Intervention: Standard COPD treatment only
Number of subjects: 70
Study 24586896 — intervention group
Group type: EXPERIMENTAL
Intervention: Lifestyle intervention group (dietary advice, coaching, and exercise)
Number of subjects: 301
Study 24586896 — intervention group
Group type: COMPARATOR
Intervention: Control group (standard care)
Number of subjects: 301
Study 24586896 — intervention group
Group type: EXPERIMENTAL
Intervention: Lifestyle intervention group
Number of subjects: 301
Study 24586896 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 301
Study 24586896 — intervention group
Group type: EXPERIMENTAL
Intervention: Children from the RCT
Number of subjects: 301
Study 24586896 — intervention group
Group type: COMPARATOR
Intervention: Reference group children (born to women with normal BMI)
Number of subjects: 301
Study 23306857 — intervention group
Group type: EXPERIMENTAL
Intervention: etched GMTA (EGMTA)
Number of subjects: 64
Study 23306857 — intervention group
Group type: EXPERIMENTAL
Intervention: gray-colored MTA (GMTA)
Number of subjects: 64
Study 23306857 — intervention group
Group type: EXPERIMENTAL
Intervention: etched WMTA (EWMTA)
Number of subjects: 64
Study 23306857 — intervention group
Group type: EXPERIMENTAL
Intervention: white-colored MTA (WMTA)
Number of subjects: 64
Study 19959772 — intervention group
Group type: EXPERIMENTAL
Intervention: Voxel-based DTI analysis in mTBI patients
Number of subjects: 10
Study 19959772 — intervention group
Group type: COMPARATOR
Intervention: Control participants (age-matched)
Number of subjects: 10
Study 16548702 — intervention group
Group type: EXPERIMENTAL
Intervention: Providing a 'risk anchor' based on downward social comparison processes
Number of subjects: 134
Study 16548702 — intervention group
Group type: COMPARATOR
Intervention: Public commitment, self-consistency, unique causal risk models
Number of subjects: 134
Study 16548702 — intervention group
Group type: COMPARATOR
Intervention: Pessimism and differences in understanding percentages
Number of subjects: 134